Study of CGEN-15029

Trial Profile

Study of CGEN-15029

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs COM 701 (Primary)
  • Indications Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Compugen
  • Most Recent Events

    • 07 Nov 2017 According to a Compugen media release, the company is working on finalizing the clinical protocol and the study is expected to start in 2018.
    • 02 Aug 2017 According to a Compugen Ltd. media release, the company is planning to file an IND application towards the end of the first quarter of 2018. Production of the drug for trial and finalizing trial design is ongoing.
    • 31 May 2017 According to a Compugen Ltd. media release, the company expects delay of several months in the submission of an Investigational New Drug (IND) application for COM-701 due to contamination of the material manufactured for the GLP toxicity studies during the manufacturing process.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top